Compare OXSQ & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXSQ | SERA |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.1M | 130.5M |
| IPO Year | N/A | 2021 |
| Metric | OXSQ | SERA |
|---|---|---|
| Price | $1.78 | $3.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 788.1K | 51.5K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | ★ 23.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,142,565.00 | $95,000.00 |
| Revenue This Year | N/A | $19.22 |
| Revenue Next Year | $2.27 | $400.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.06 |
| 52 Week Low | $1.56 | $1.37 |
| 52 Week High | $2.87 | $9.13 |
| Indicator | OXSQ | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 39.22 | 58.09 |
| Support Level | $1.82 | $3.20 |
| Resistance Level | $1.87 | $3.72 |
| Average True Range (ATR) | 0.04 | 0.28 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 16.83 | 76.93 |
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.